HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (14) Citing Articles via Google Scholar Google Scholar Articles by Sharma, J. N. Search for Related Content PubMed PubMed Citation Articles by Sharma, J. N.

Does the Kinin System Mediate in Cardiovascular Abnormalities? An Overview

From the Department of Applied Therapeutics, Faculty of Pharmacy, Health Sciences Center, Kuwait University, Safat, Kuwait.

All the components of the kallikrein-kinin system are located in the cardiac muscle, and its deficiency may lead to cardiac dysfunction. In recent years, numerous observations obtained from clinical and experimental models of diabetes, hypertension, cardiac failure, ischemia, myocardial infarction, and left ventricular hypertrophy have suggested that the reduced activity of the local kallikrein-kinin system may be instrumental for the induction of cardiovascular-related diseases. The cardioprotective property of the angiotensin-converting enzyme inhibitors is primarily mediated via the kinin-releasing pathway, which may cause regression of left ventricular hypertrophy in hypertensive situations. The ability of kallikrein gene delivery to produce a wide spectrum of beneficial effects makes it an excellent candidate in treating hypertension and cardiovascular and renal diseases. In addition, stable kinin agonists may also be available in the future as therapeutic agents for cardiovascular and renal disorders.

Key Words: Kallikrein-kinin system • cardioprotection • hypertension • cardiac diseases • angiotensin-converting enzyme inhibitors

Address for reprints: J. N. Sharma, Department of Applied Therapeutics, Faculty of Pharmacy, Health Sciences Center, Kuwait University, P.O. Box 24923, Safat 13110, Kuwait.

This article has been cited by other articles:

				T. W. Stief Kallikrein Activates Prothrombin Clinical and Applied Thrombosis/Hemostasis, January 1, 2008; 14(1): 97 - 98. [Abstract] [PDF]